Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Hear top experts in hematologic malignancies discuss the latest developments in clinical care.
Advance registration for the 57th ASH Annual Meeting is now open.
Submit your feedback on draft recommendations for the initial workup of acute leukemia. Open comment period ends Monday, August 31, 2015
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.
Search a database of practicing hematologists in your area.
Help move hematology forward by supporting research, career development, and quality care and education programs.
Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.
Pharmaceutical Media Inc. has been selected by the American Society of Hematology (ASH) as the advertising sales representatives for its journal Blood and annual meeting properties, effective January 2016.
The American Society of Hematology, the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the 13 investigators who will receive ASH Bridge Grants for promising blood disease research that could otherwise not be funded by the National Institutes of Health as a result of severe federal funding restrictions.
The American Society of Hematology (ASH) and the College of American Pathologists (CAP) today opened a public comment period for the draft recommendations of an evidence-based guideline that addresses the initial work-up of acute leukemiaThe American Society of Hematology (ASH) and the College of American Pathologists (CAP) today opened a public comment period for the draft recommendations of an evidence-based guideline that addresses the initial work-up of acute leukemia
The first protein engineered to help control bleeding episodes in patients with severe von Willebrand disease has been shown to be safe and effective, according to results of a Phase III trial. Study data were published online today in Blood, the Journal of the American Society of Hematology.
The National Heart, Lung and Blood Institute (NHLBI) released its draft strategic research priorities and is requesting additional input from the scientific community by August 28, 2015. The strategic planning process aims to identify compelling questions and critical challenges that should be addressed within the next decade. ASH submitted several research recommendations based on the ASH Agenda for Hematology Research and ASH Sickle Cell Priorities and is pleased to see many of them incorporated into the NHLBI's draft strategic research priorities. All ASH members are encouraged to review and comment by the deadline. Please see link above for more details.
On July 8, 2015, the Centers for Medicare and Medicaid Services (CMS) released its
governing payments for physician services and other associated policies covering the calendar year of 2016. This is the first physician fee schedule proposed rule following
the passage of the Medicare Access and CHIP Reauthorization Act (MACRA), which eliminated the sustainable growth rate formula that had long mandated cuts each year. Please follow the link above to learn more.
Guaranteeing access to clinical trials for cancer patients has long been a priority for ASH. Recently, the Departments of Health and Human Services and Labor (which are both responsible for implementing the various provisions of the health reform law)
there would not be federal regulations to implement the clinical trials coverage provision of the health reform law. The agencies determined the statutory language was self-implementing, and indicated that the Departments do not expect to issue regulations in the near future. Please follow the link above to learn more about this issue.
The Centers for Medicare and Medicaid Services (CMS) has announced a new plan that will introduce some leniency in the introduction of the new ICD-10 diagnosis coding system. Most notably, claims will not be rejected if the diagnosis coding is not to the correct level of specificity. To see an example from the field of hematology, please follow the link. ASH staff has prepared a full article giving an example of the diagnosis coding for lymphoid leukemia.
Dr. Dawson talks about his journey as the inventor and developer of a standardized evacuated "tube" for blood specimen collection.
Dr. Rajkumar discusses how Dr. Robert Kyle started and developed the Multiple Myeloma Program at the Mayo Clinic. Dr. Kyle reflects on the success of the program for over 50 years.
Drs. Gale, Bennett, and Hoffman discuss factors hematologists must keep in mind when diagnosing patients with therapy-related AML or MDS, in order to prevent incorrect therapy decisions.
Drs. Badawy, Liem, and Thompson discuss several benefits, risks, and limitations of using health-related apps, focusing on hematology and oncology apps. They present a thorough study that includes recommendations of some of the best apps available, and a discussion of clinical benefits, cost-effectiveness, potential risks, and even legal concerns.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology